Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice

Myelosuppression and gastrointestinal damage are common side effects of cancer treatment limiting efficacy of DNA-damaging chemotherapeutic drugs. The Toll-like receptor 5 (TLR5) agonist Entolimod has demonstrated efficacy in mitigating damage to hematopoietic and gastrointestinal tissues caused by...

Descripción completa

Detalles Bibliográficos
Autores principales: Kojouharov, Bojidar M., Brackett, Craig M., Veith, Jean M., Johnson, Christopher P., Gitlin, Ilya I., Toshkov, Ilia A., Gleiberman, Anatoli S., Gudkov, Andrei V., Burdelya, Lyudmila G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996654/
https://www.ncbi.nlm.nih.gov/pubmed/24583651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996654/
https://www.ncbi.nlm.nih.gov/pubmed/24583651

Ejemplares similares